Hostname: page-component-89b8bd64d-b5k59 Total loading time: 0 Render date: 2026-05-10T13:01:30.071Z Has data issue: false hasContentIssue false

Critical CHD screening programme: a 3-year multicentre experience in Mexico

Published online by Cambridge University Press:  08 July 2022

René Gómez-Gutiérrez
Affiliation:
Genomi-k, Monterrey, Nuevo León, 64060, Mexico CHRISTUS Muguerza, Hospital Alta Especialidad, Monterrey, Nuevo León, 64060, Mexico
José M. Galindo-Hayashi
Affiliation:
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo León, 64710, Mexico
Consuelo Cantú-Reyna
Affiliation:
Genomi-k, Monterrey, Nuevo León, 64060, Mexico Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo León, 64710, Mexico
Diana L. Vazquez-Cantu
Affiliation:
Genomi-k, Monterrey, Nuevo León, 64060, Mexico Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo León, 64710, Mexico
Cecilia Britton-Robles
Affiliation:
Genomi-k, Monterrey, Nuevo León, 64060, Mexico Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo León, 64710, Mexico
Héctor Cruz-Camino*
Affiliation:
Genomi-k, Monterrey, Nuevo León, 64060, Mexico Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo León, 64710, Mexico
*
Author for correspondence: Héctor Cruz-Camino, M.Sc., Genomi-k, Monterrey, Nuevo León, 64060, Mexico. Tel: (+52) 81 1522 5803; Fax: 2129372144. E-mail: hcruz@genomi-k.com
Rights & Permissions [Opens in a new window]

Abstract

Introduction:

CHDs are the most common type of birth defect. One in four newborns with a heart defect has a critical CHD. In Mexico, there is a lack of data available to determine its prevalence. Pulse oximetry screening programmes have been implemented worldwide, reporting opportunity areas in algorithm interpretation and data management. Our study aims to share preliminary results of a 3-year experience of a multicentre pulse oximetry screening programme that addresses critical challenges.

Materials and methods:

This retrospective study examined the reports of newborns screened from February 2016 to July 2019 from five hospitals. Two algorithms –the New Jersey and the American Academy of Pediatrics– were implemented over consecutive periods. The algorithms’ impact was assessed through the calculation of the false-positive rate in an eligible population.

Results:

A total of 8960 newborns were eligible for the study; from it, 32.27% were screened under the New Jersey and 67.72% under the American Academy of Pediatrics algorithm – false-positive rate: 1% (CI 95: ± 0.36%) and 0.71% (CI 95: ± 0.21%), respectively. Seventy-nine newborns were referred, six were diagnosed with critical CHD, and six with CHD. The critical CHD estimated prevalence was 6.69:10,000 newborns (CI 95: ± 5.36). Our results showed that the algorithm was not related to the observable false-positive rate reduction.

Discussion:

Other factors may play a role in decreasing the false-positive rate. Our experience implementing this programme was that a systematic screening process led to more confident results, newborn’s report interpretation, and follow-up.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press
Figure 0

Figure 1. Flow chart of screened newborns’ outcomes. The eligible population is delimited by dashed lines. CCHD = critical CHD; h = hours.

Figure 1

Table 1. CHDs and other findings detected via screening in asymptomatic term newborns

Figure 2

Table 2. Comparison between the New Jersey and the American Academy of Pediatrics algorithms regarding their specificity, and a reinterpretation

Figure 3

Table 3. P-values calculated for the chi-squared tests between groups